BFM
VIRX

Boothbay Fund Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Boothbay Fund Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,310
Closed -$40K – 2673
2022
Q2 		$40K Buy
+10,310
New +$29.4K ﹤0.01% 2096
2021
Q2 		– Sell
-17,858
Closed -$165K – 2177
2021
Q1 		$165K Buy
17,858
+11,744
+192% +$122K 0.01% 1397
2020
Q4 		$43K Buy
+6,114
New +$31.9K ﹤0.01% 1196
2020
Q3 		– Sell
-1,392
Closed -$13K – 1266
2020
Q2 		$13K Hold
1,392
– – ﹤0.01% 935
2020
Q1 		$20K Hold
1,392
– – ﹤0.01% 810
2019
Q4 		$16K Hold
1,392
– – ﹤0.01% 823
2019
Q3 		$35K Hold
1,392
– – ﹤0.01% 734
2019
Q2 		$35K Hold
1,392
– – ﹤0.01% 690
2019
Q1 		$59K Hold
1,392
– – 0.01% 689
2018
Q4 		$20K Sell
1,392
-43
-3% -$1.75K ﹤0.01% 618
2018
Q3 		$100K Hold
1,435
– – 0.01% 712
2018
Q2 		$106K Hold
1,435
– – 0.01% 681
2018
Q1 		$137K Buy
1,435
+323
+29% +$55.4K 0.02% 629
2017
Q4 		$144K Buy
1,112
+180
+19% +$16.9K 0.02% 616
2017
Q3 		$63K Hold
932
– – 0.01% 572
2017
Q2 		$88K Buy
932
+365
+64% +$41.9K 0.02% 616
2017
Q1 		$81K Hold
567
– – 0.02% 681
2016
Q4 		$72 Buy
567
+110
+24% +$15.3K 0.02% 703
2016
Q3 		$70K Buy
+457
New +$64.5K 0.02% 663

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Boothbay Fund Management's VIRX Position: Q3 2022 in Review

Boothbay Fund Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2022, closing a stake of 10,310 shares — an estimated $40K sold.

Boothbay Fund Management first reported a position in VIRX in Q3 2016 and held it in 19 quarters. The position peaked at $165K in Q1 2021. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2022.

  • Boothbay Fund Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 10,310 Viracta Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $40K.
  • Boothbay Fund Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2016 and held it in 19 quarters.
  • Boothbay Fund Management's Viracta Therapeutics, Inc. Common Stock position peaked at $165K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.